Last reviewed · How we verify

ONY — Portfolio Competitive Intelligence Brief

ONY pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Infasurf CALFACTANT marketed Surfactant [EPC] Respiratory 1998-01-01
Aerosolized Calfactant Aerosolized Calfactant phase 3 Pulmonary surfactant replacement Pulmonary surfactant (lipid-protein complex) Respiratory/Pulmonology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Chiesi Usa Inc · 1 shared drug class
  3. Ottawa Hospital Research Institute · 1 shared drug class
  4. Poznan University of Medical Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ONY:

Cite this brief

Drug Landscape (2026). ONY — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ony. Accessed 2026-05-13.

Related